Tune into this episode of Covington’s Life Sciences Audiocast, where Sibel Yilmaz, Majken Lagerbielke, and Leire Garagorri Eguidazu discuss the new market definition notice published by DG COMP, specifically the latest on the new guidance concerning pharmaceutical innovation markets and possible implications for analysing M&A and licensing deals.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Sibel Yilmaz Sibel Yilmaz

Sibel Yilmaz advises on all aspects of competition law, foreign investment and foreign subsidies screening, with a focus on the life sciences and technology and industrial sectors.

Sibel has particular expertise in the life sciences sector and provide strategic advice in regard to…

Sibel Yilmaz advises on all aspects of competition law, foreign investment and foreign subsidies screening, with a focus on the life sciences and technology and industrial sectors.

Sibel has particular expertise in the life sciences sector and provide strategic advice in regard to M&A, licensing and collaborations, regulatory strategies and general compliance. Sibel has also represented clients in several investigations relating to alleged excessive prices and other non-competitive practices in the life science sector. Sibel advises various clients in the technology sector, including in the gaming sector. She is also a Non Governmental Adviser to the Swedish Competition Authority within the frame work of its role in the ICN.

Sibel is ranked among the world’s top antitrust practitioners by Global Competition Review, who included her in their most recent 40 Under 40 survey, as well as Chambers Global. She is described as “a brilliant and promising lawyer, who is highly recommended for complex merger work” and “an exceptional talent”, “absolutely a tip for the top.”

Sibel obtained received her Master of Law from Stockholm University and a LL.M. in Law and Economics from the University of Rotterdam. She is admitted to practice in Belgium (e-list) and Sweden.